Results 111 to 120 of about 23,125,138 (369)

Emerging immunopharmacological targets in multiple sclerosis. [PDF]

, 2015
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami, Abrams, Abrams, Achiron, Adelman, Allen, Bachmann, Bai, Bai, Baker, Balcer, Bar-Or, Bar-Or, Bar-Or, Bar-Or, Ben-Nun, Biasi, Bielekova, Bielekova, Bielekova, Bielekova, Bielekova, Bitar, Bluestone, Bogoljub Ciric, Bour-Jordan, Bourdette, Bourquin, Brambilla, Brocke, Burman, Burns, Burrows, Chaudhuri, Chitnis, Coles, Constantinescu, Constantinescu, Correale, Correale, Cox, Cragg, Crowe, Darlington, Darlington, Disanto, Duddy, Emery, Espinoza-Delgado, Faria, Faria, Farjam, Feinstein, Fissolo, Fletcher, Freedman, Garren, Garren, Garren, Garren, Giovannoni, Giovannoni, Girvin, Girvin, Goodin, Gosselin, Goverman, Goverman, Guang-Xian Zhang, Hale, Hartmann, Hauser, Havrdova, Hawker, He, Hedegaard, Higgins, Hill-Cawthorne, Hilliard, Hilliard, Ho, Hoffmann, Hofman, Jankovic, Jennum, Kappos, Kappos, Karussis, Karussis, Kearney, Kerbrat, Le Page, Li, Liblau, Lider, Lider, Lindsey, Lindsey, Lisak, Liu, Lobell, Lobell, Lohse, Lund, Lyons, Marrie, Marta, Martin, Mease, Medaer, Mestecky, Mikulkova, Miller, Milo, Mirshafiey, Mojtaba Farjam, Moreau, Mowat, Nicoletti, Nightingale, O'Brien, Offner, Offner, Oh, Oksenberg, Pender, Pettitt, Phillips, Phillips, Podojil, Poli, Pozzilli, Pryce, Quintana, Racioppi, Rasouli, Robinson, Rose, Rose, Rostami, Sandrini, Schaub, Sclerosis, Selmaj, Selmaj, Sinha, Smith, Spuler, Stuve, Taoufik, Tsunoda, Turley, Turley, Turner, van Boxel-Dezaire, van den Hoogen, Van der Walt, van Oosten, van Oosten, van Oosten, Vandenbark, Vandenbark, Viglietta, Viglietta, Vollmer, Walczak, Waldmann, Wang, Weber, Wefer, Weiner, Weiner, Weissert, Willis, Wucherpfennig, Wynn, Xing, Yadav, Zang, Zhang, Zhang, Zhang, Zhang   +182 more
core   +2 more sources

EFFICIENCY, SAFETY AND POSSIBILITIES OF IMMUNOTROPIC THERAPY AFTER SURGICAL TREATMENT OF ENDOMETRIOSIS

Медицинский совет, 2018
The identification of the immune system disorders along with the impact on the causative agent and correction of such disorders is of great importance in the therapy of patients with endometritis.
L. I. Anokhova, T. E. Belokrinitskaya, A. V. Pateyuk   +2 more
doaj   +1 more source

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, EarlyView.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Expression of chicken interleukin-2(IL-2) in E. coli. and preparation of its polyclonal antibody

浙江大学学报. 农业与生命科学版, 2003
Interleukin-2 (IL-2) is known to play a number of functions in the modulation of immunity. In this study the chicken IL-2 gene was cloned into a prokaryon vector pET-28b and the recipient cell of E. coli.
YU Lian, XIE Rong-hui, LU Mi-jia, HUANG Yao-wei, LI Jian-rong   +4 more
doaj   +1 more source

Exploring Patients’ Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne‐France Georgel, Augustin Latourte, Hang‐Korng Ea, Sébastien Ottaviani, Charlotte Jauffret, Vincent Ducoulombier   +14 more
wiley   +1 more source

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

SODIUM POLYPRENYL PHOSPHATE (PHOSPRENYL) EXERTS AN IL-2-DEPENDENT RESTORATIVE EFFECT UPON IN VIVO DTH INHIBITION

Медицинская иммунология, 2014
. We have shown that polyprenyl phosphate (phosprenyl) competes with interleukin 2 for binding with serum γ-globulin. It was also demonstrated that phosprenyl restores delayed type hypersensitivity induced by Listeria monocytogenes, after its inhibition ...
S. M. Sobolev, T. N. Nikolaeva, E. A. Grigorieva, A. V. Pronin   +3 more
doaj   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Arthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H. Weisman, Philip M. Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, David Wofsy, Diane Kamen, Richard A. Furie, Deepak A. Rao, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Chun‐Hao Lee, Derek Fine, Manny Monroy‐Trujillo, Ummara Shah, Mariko Ishimori, Robert M. Clancy, Michael Belmont, Ming Wu, Nicole Bornkamp, Evan Der, Beatrice Goilav, Nicole Jordan, Daniel Schwartz, James Pullman, David Wofsy, Dawn Smilek, Patti Tosta, Matthias Kretzler, Celine C. Berthier, E. Steve Woodle, Dave Hildeman, Michael Brenner, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +48 more
wiley   +1 more source

A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a “βγ-only” interleukin-2 variant

Frontiers in Immunology
IntroductionInterleukin-2 (IL-2) is one of the first cytokines to be discovered as an immune agonist for cancer immunotherapy. Biased IL-2 variants had been discovered to eliminate Treg activation or enhance the tumor specific T cell cytotoxicity ...
Yongji Jiang, Chuyuan Chen, Yuan Liu, Rong Wang, Chuan Feng, Lili Cai, Shuang Chang, Lei Zhao   +7 more
doaj   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source